KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer

被引:11
|
作者
Sullivan, I. [1 ]
Salazar, J. [2 ,3 ]
Arqueros, C. [1 ]
Andres, M. [1 ]
Sebio, A. [1 ]
Majem, M. [1 ]
Szafranska, J. [4 ]
Martinez, E. [5 ]
Paez, D. [1 ]
Lopez-Pousa, A. [1 ]
Baiget, M. [2 ,3 ]
Barnadas, A. [1 ,6 ]
机构
[1] Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain
[2] Hosp Santa Creu & Sant Pau, Genet Dept, St Antoni Maria Claret 167, Barcelona 08025, Spain
[3] CIBERER, U 705, Barcelona, Spain
[4] Hosp Santa Creu & Sant Pau, Pathol Dept, Barcelona, Spain
[5] Hosp Santa Creu & Sant Pau, Thorac Surg Dept, Barcelona, Spain
[6] UAB, Barcelona, Spain
来源
CLINICAL & TRANSLATIONAL ONCOLOGY | 2017年 / 19卷 / 07期
关键词
Resectable non-small cell lung cancer; Prognostic marker; VEGF pathway; KRAS; Genetic variants; ENDOTHELIAL GROWTH-FACTOR; PHARMACOGENETIC FACTORS; PATHWAY POLYMORPHISMS; VEGF POLYMORPHISMS; EXPRESSION; SURVIVAL; ANGIOGENESIS; CHEMOTHERAPY; ASSOCIATION; BEVACIZUMAB;
D O I
10.1007/s12094-017-1620-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Several angiogenic prognostic markers are under investigation because of their potential clinical utility, aiming to improve patient outcomes. We hypothesized that genetic variant in the VEGF pathway could be used as prognostic markers of survival in non-small cell lung cancer (NSCLC) patients undergoing pulmonary resection. Methods We evaluated the relationship between genetic variants in the VEGF pathway and relapse-free survival (RFS, main endpoint) and overall survival (OS, secondary endpoint) among 131 patients with stage I-III NSCLC treated with surgical resection from 2009 to 2013. Clinical, pathological and surgical data were prospectively collected. Twenty-five variants in sixteen relevant genes were selected and genotyped in tumor samples by real time PCR. The Kaplan-Meier method with the log-rank test and Cox's regression models were used for RFS and OS analyses. Results With a median follow-up of 36 (min = 2.8; max = 67.4) months, there were 31 (24%) relapses and 31 (24%) deaths. Overall, median RFS was not reached and median OS was 65 [95% confidence interval (CI) 56-75] months. The KRAS rs1137282 and PIK3C2A rs4356203 variants were significantly associated with RFS. For KRAS rs1137282, the 3-year RFS was 76% [95% CI 64-84%] in patients harboring an A/A genotype compared to 53% [95% CI 37-69%] in patients harboring an A/G or G/G genotype (p = 0.02). For PIK3C2A rs4356203, patients with an A/A or an A/G genotype had a 3-year RFS of 72% [95% CI 58-76%], whereas in patients with a G/G genotype was 49% [95% CI 28-70%] (p = 0.02). These associations remained statistically significant after adjusting for all the relevant clinical parameters in the multivariable analysis. Conclusion Genetic variants in VEGF pathway may be associated with recurrence in stage I-III NSCLC. Specifically, the KRAS rs1137282 could be considered as a prognostic factor for recurrence in resectable NSCLC patients. Although PIK3C2A rs4356203 was associated with RFS, further analyses are necessary to confirm these data.
引用
收藏
页码:884 / 890
页数:7
相关论文
共 50 条
  • [1] KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer
    I. Sullivan
    J. Salazar
    C. Arqueros
    M. Andrés
    A. Sebio
    M. Majem
    J. Szafranska
    E. Martínez
    D. Páez
    A. López-Pousa
    M. Baiget
    A. Barnadas
    Clinical and Translational Oncology, 2017, 19 : 884 - 890
  • [2] Value of the Glasgow Prognostic Score as a Prognostic Factor in Resectable Non-Small Cell Lung Cancer
    Yotsukura, Masaya
    Ohtsuka, Takashi
    Kaseda, Kaoru
    Kamiyama, Ikuo
    Hayashi, Yuichiro
    Asamura, Hisao
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (08) : 1311 - 1318
  • [3] Prognostic markers in resectable non-small cell lung cancer
    Strauss, GM
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1997, 11 (03) : 409 - &
  • [4] Prognostic role of miRNAs in resectable non-small cell lung cancer
    Gallach, Sandra
    Jantus-Lewintre, Eloisa
    Calabuig-Fariarinas, Silvia
    Blasco, Ana
    Guijarro, Ricardo
    Martorell, Miguel
    Camps, Carlos
    CANCER RESEARCH, 2015, 75
  • [5] New prognostic factors in resectable non-small cell lung cancer
    Smit, EF
    Groen, HJM
    Splinter, TAW
    Ebels, T
    Postmus, PE
    THORAX, 1996, 51 (06) : 638 - 646
  • [6] Molecular prognostic factors in resectable non-small cell lung cancer
    Vielh, P
    Spano, JP
    Grenier, J
    Le Chevalier, I
    Soria, JC
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005, 53 (03) : 193 - 197
  • [7] MiRNAs related to KRAS mutational status in resectable non-small cell lung cancer
    Gallach, S.
    Calabuig-Farinas, S.
    Jantus-Lewintre, E.
    Montaner, D.
    Escorihuela, E.
    Castellano, J.
    Figueroa, S.
    Blasco, A.
    Hernando, C.
    Guijarro, R.
    Camps, C.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 177 - 177
  • [8] KRAS in non-small cell lung cancer
    Amanam, I.
    Gupta, R.
    Mambetsariev, I.
    Koczywas, M.
    Cristea, M.
    Massarelli, E.
    Reckamp, K. L.
    Salgia, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis
    Pelletier, MP
    Edwardes, MDD
    Michel, RP
    Halwani, F
    Morin, JE
    CANADIAN JOURNAL OF SURGERY, 2001, 44 (03) : 180 - 188
  • [10] Preoperative thrombocytosis is a significant unfavorable prognostic factor for patients with resectable non-small cell lung cancer
    Kim, Miso
    Chang, Hyun
    Yang, Hee Chul
    Kim, Yu Jung
    Lee, Choon-Taek
    Lee, Jae-Ho
    Jheon, Sanghoon
    Kim, Kwhanmien
    Chung, Jin-Haeng
    Lee, Jong Seok
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2014, 12